Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Berry

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Gynecologic Oncology|August 22, 2021
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trialMathew Cowan, Wendy M Swetzig, Valery Adorno-Cruz, et al.
Physical & Occupational Therapy in Pediatrics|January 11, 2023
Baseline Range of Motion, Strength, Motor Function, and Participation in Youth with Hutchinson-Gilford Progeria SyndromeJulie Malloy, Emily Berry, Annette Correia, et al.
The American Journal of Gastroenterology|August 3, 2016
Financial Incentives for Promoting Colorectal Cancer Screening: A Randomized, Comparative Effectiveness TrialSamir Gupta, Stacie Miller, Mark Koch, et al.
Gynecologic Oncology|October 27, 2019
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG studyRoisin E O'Cearbhaill, Wei Deng, Lee-May Chen, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Gynecologic Oncology|August 22, 2021
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trialMathew Cowan, Wendy M Swetzig, Valery Adorno-Cruz, et al.
Physical & Occupational Therapy in Pediatrics|January 11, 2023
Baseline Range of Motion, Strength, Motor Function, and Participation in Youth with Hutchinson-Gilford Progeria SyndromeJulie Malloy, Emily Berry, Annette Correia, et al.
The American Journal of Gastroenterology|August 3, 2016
Financial Incentives for Promoting Colorectal Cancer Screening: A Randomized, Comparative Effectiveness TrialSamir Gupta, Stacie Miller, Mark Koch, et al.
Gynecologic Oncology|October 27, 2019
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG studyRoisin E O'Cearbhaill, Wei Deng, Lee-May Chen, et al.
Pageof 4